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Abstract
The aquaporins (AQPs) are a family of small, integral membrane proteins that facilitate water
transport across the plasma membranes of cells in response to osmotic gradients. Data from
knockout mice support the involvement of AQPs in epithelial fluid secretion, cell migration, brain
oedema and adipocyte metabolism, which suggests that modulation of AQP function or expression
could have therapeutic potential in oedema, cancer, obesity, brain injury, glaucoma and several
other conditions. Moreover, loss-of-function mutations in human AQPs cause congenital cataracts
(AQP0) and nephrogenic diabetes insipidus (AQP2), and autoantibodies against AQP4 cause the
autoimmune demyelinating disease neuromyelitis optica. Although some potential AQP
modulators have been identified, challenges associated with the development of better modulators
include the druggability of the target and the suitability of the assay methods used to identify
modulators.
Aquaporins (AQPs) are a class of membrane water channels whose primary function is to
facilitate the passive transport of water across the plasma membrane of the cell in response
to osmotic gradients that are created by the active transport of solutes. Aquaglyceroporins,
which form a subset of the 13 mammalian AQPs, also facilitate the passive transport of
glycerol and possibly other small solutes such as urea and carbon dioxide. As we discuss
below, the water-selective AQPs are involved in many biological functions, including
transepithelial fluid transport, cell migration, brain oedema and neuroexcitation. The
aquaglyceroporins are involved in cell proliferation, adipocyte metabolism and epidermal
water retention.
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As highlighted here, data from AQP-knockout mice and from humans with loss-of-function
mutations in AQPs suggest that modulators of AQP function may have broad clinical
indications, including in nephrology (for the treatment of oedema and hypertension),
neurology (for the treatment of brain swelling and epilepsy), oncology (for the treatment of
tumour angiogenesis and proliferation), ophthalmology (for the treatment of corneal and
lens transparency as well as glaucoma) and in the treatment of obesity and dermatological
indications (namely, epidermal hydration and proliferation). In addition, two human diseases
that are linked to aqua-porins (known as aquaporinopathies) present drug development
opportunities, including potential therapies: nephrogenic diabetes insipidus (NDI), which is
caused by loss-of-function AQP2 mutations; and neuromyelitis optica (NMO), which is
caused by the presence of auto-antibodies against AQP4.
Here, we review the structure and function of AQPs, the evidence in support of AQPs as
drug targets, as well as progress and challenges in the discovery of AQP-targeted small
molecules, biologics and gene therapies. Although there is compelling evidence from studies
using knockout mice that AQPs are drug targets, progress in the discovery of AQP
modulators has been slow, in part because current efforts to identify inhibitors are hampered
by challenges in screening assays and in targeting the compact, pore-containing AQP
molecule.
AQP structure and function
There is a large amount of information available about the molecular structure of AQPs
(reviewed in REFS 1,2), which could potentially facilitate the discovery of AQP-targeted
small molecules. AQPs are organized as tetramers on membranes (FIG. 1a). At least one of
the AQPs, AQP4, can associate into higher-order supramolecular assemblies known as
orthogonal arrays of particles, in which AQP4 tetramers form square arrays that are
stabilized by the interactions of aminoterminal residues in the monomeric units3–5. Early,
low-resolution AQP structures solved by electron crystallography include AQP0 (also
known as MIP; Protein Data Bank (PDB) codes: 1SOR and 2B6O), AQP1 (PDB codes:
1IH5, 1FQY and 1H6I) and AQP4 (PDB code: 2D57). High-resolution X-ray crystal
structures are available for AQP0 (PDB codes: 1YMG and 2B6P), AQP1 (PDB code: 1J4N),
AQP4 (PDB code: 3GD8) and AQP5 (PDB code: 3D9S). Although the low-resolution
structures garnered an understanding of the general topology of AQPs, the high-resolution
structures provided greater insight into the atomic-level mechanisms of water and solute
conduction and of proton and/or ion exclusion, and provide a basis for virtual screening and
molecular dynamics simulations. Electron and X-ray crystal diffraction structures for several
non-mammalian AQPs have also been solved, including the bacterial aquaporin AqpZ (PDB
codes: 1RC2 and 2ABM) and the glycerol facilitator GlpF (PDB codes: 1LDA, 1LDI and
1FX8), as well as malarial Plasmodium falciparum AQP (PfAQP; PDB code: 3C02).
The monomeric units of AQPs are ~30 kDa and consist of six transmembrane α-helices
(known as M1, M2, M4–M7 and M8), two half helices (M3 and M7) and five connecting
loops (loops a–e) (FIG. 1b,c). The N- and carboxyterminal domains are located in the
cytoplasm. Although AQPs facilitate water transport (and aquaglyceroporins additionally
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transport glycerol) by a mechanism involving an aqueous pore, they prevent the conduction
of protons, which is crucial to avoid dissipation of proton gradients.
Each AQP monomer consists of an extracellular and cytoplasmic vestibule that is connected
by a central amphipathic pore region of 20–25 Å containing hydrophilic and hydrophobic
surfaces, as exemplified by the X-ray structure of bovine AQP1 (REF. 6) (FIG. 1d). The
hydrophilic surface consists of α-carbonyl groups from the polypeptide backbone, and the
hydrophobic residues of the amphipathic pore prevent the permeation of larger molecules6.
There are two conserved Asn-Pro-Ala (NPA) motifs in the half-helices M3 and M7, which
contain inward-facing asparagine polar side chains. These motifs are part of the hydrophilic
surface of the amphipathic pore and are important for preventing proton conduction7.
Together with the backbone α-carbonyl groups, the NPA motifs act as hydrogen-bond
donors and acceptors that coordinate the transport of water (or glycerol for the
aquaglyceroporins) through the pore6,8.
The extracellular vestibule6 contains a constriction region that is made up of aromatic and
arginine residues (known as the ar/R constriction or the selectivity filter), which is also
important for preventing proton conduction7,9. The ar/R constriction makes up the narrowest
region of the pore, and has a diameter of ~2.8 Å in human AQP1, ~1.5 Å in human AQP4
and ~3.4 Å for the less selective aquaglyceroporins6,8,10. The narrow interior pore region of
AQPs presents a potential challenge in the identification of small molecules that target the
aqueous pore region.
Molecular dynamics simulations have been useful in elucidating the mechanisms of water
and glycerol transport through AQPs. An interesting conclusion from these studies is that
water molecule dipoles orient symmetrically on opposing sides of the NPA motif, which
prevents proton transfer through a Grotthuss-type ‘proton-wire’ mechanism11. One theory
for the mechanism of proton blockade emerging from molecular dynamics simulations is
that hydronium ions need to be de-solvated, which is energetically unfavourable in the
protein environment12,13. Free-energy profiles for water permeation through the aqueous
pore region13,14, obtained from molecular dynamics simulations, have also been used to
investigate the potential water- and solute-transporting function of the central region of AQP
tetramers15.
Recent molecular dynamics simulations have suggested that a novel gating mechanism
operates in AQP5, in which monomeric channels are in distinct open or closed
conformations16. This finding adds to the knowledge of the structural basis of AQP
gating17; previous experimentally and computationally derived mechanisms proposed that
AQP gating involved mechanosensitivity and phosphorylation in yeast AQPs18, and
membrane tension in both mammalian and yeast AQPs19–21.
The combination of molecular dynamics and other computational methods, such as virtual
screening, has been used to identify possible AQP inhibitors (BOX 1). The abundance of X-
ray crystal structure data suggests that virtual screening and computationally biased high-
throughput screening will aid the identification of inhibitors.
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Box 1
The use of computational methods in AQP drug discovery
The growing knowledge of aquaporin (AQP) structure, particularly the atomic-level
geometry of specific hydrophobic and hydrophilic residues in the pore region, makes
AQPs amenable to computational methods of drug discovery. High-resolution X-ray
diffraction crystal structures are now available for the major mammalian AQPs: AQP0,
AQP1, AQP4 and AQP5. Owing in part to recent improvements in parallel computing,
which have been facilitated by graphical processor units, and techniques such as course-
grained simulations for biological membranes178, it has become practical to perform
molecular dynamics simulations on physiologically relevant timescales of up to 1
millisecond.
Protein–ligand docking has been used to propose binding modes of small-molecule AQP
inhibitors132,135,136,145,179 and, in some cases, the docking results have been studied
using molecular dynamics simulations to propose the dynamics of inhibitor
binding132,179. In one study, docking was used for the virtual screening of AQP1
inhibitors, then molecular dynamics was used to confirm that the orientation of the
inhibitors remained static under equilibration conditions142. However, in most cases the
inhibitors identified by the computational screen were later found to be inactive by
definitive functional assays (as discussed in the main text). AQP binding and the
selectivity of the AQP3-targeting gold (III) inhibitors was investigated using homology
modelling and docking, with inhibitor binding characterized by density functional theory
calculations. It was hypothesized that the inhibitors interact with the accessible Cys40
residue on the extracellular side of AQP3, with the traditional metal-binding residue
Cys189 in AQP1 not favourably positioned to interact with these compounds126,127.
Although the extensive structural information available for AQP makes virtual screening
promising in principle, the use of computational technology to identify bona fide
inhibitors is challenging, as the binding of small molecules does not necessarily translate
to channel blocking activity. This may be especially true for AQPs because of their small
molecular size and narrow aqueous pore. This issue is highlighted by the gold-containing
inhibitor Au(phen), which blocks glycerol transport by AQP3 but not water
transport126,127, perhaps owing to insufficient channel occlusion. More sophisticated
molecular dynamics-based approaches have been explored to model AQP inhibition,
which involve the calculation of water permeability coefficients145; however, these
approaches were computationally intensive and water permeability coefficients did not
correlate with inhibitory efficacy. Improvements in the computational methodology used
in molecular dynamics could lead to more reliable virtual screening for the discovery of
AQP inhibitors.
As mentioned above, the major cellular function of AQPs is to facilitate the osmotic
transport of water — and glycerol for the aquaglyceroporins — across plasma membranes of
cells. Below, we discuss how these basic functions translate into many biological activities
that have potential clinical applications. There is also evidence (some of which is
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conflicting) to suggest that in addition to the transport of water and glycerol, AQPs could
potentially transport gases such as carbon dioxide22–24, ammonia24,25 and nitric oxide26,27,
as well as larger polar solutes such as sugars28, hydrogen peroxide22,29,30 and even some
ions31. However, it is not known whether the transport of molecules other than water and
glycerol is biologically important.
Biological function of AQPs in mammals
AQPs are widely expressed in the body (FIG. 2), particularly in cell types that are involved
in fluid transport, such as epithelial cells in several organs, as well as in some cell types that
do not have an obvious role in fluid transport, such as adipocytes. Because there is a lack of
verified inhibitors, studies of the phenotypes of AQP-knockout mice have provided most of
the information on AQP physiology and on the potential indications of AQP-targeted
modulators (TABLE 1). Below, we further discuss the results from those phenotypic studies
that, in our view, have the greatest relevance to clinical indications of AQP modulators.
Epithelial fluid transport
AQPs facilitate transepithelial water transport in response to osmotic gradients that are
created by the transport of active ions and neutral solutes (FIG. 3a). AQP1 is expressed in
the epithelium of the renal proximal tubule and the thin descending limb of the loop of
Henle, as well as in the endothelium in the descending vasa recta; mice that are deficient in
AQP1 have a greatly impaired ability to concentrate urine32. In these mice, the reduced
permeability of the renal proximal tubule to water impairs the normal absorption of water
filtered by the glomerulus33; reduced water permeability in the thin descending limb of the
loop of Henle and the vasa recta impairs the renal counter-current multiplication and
exchange systems that are responsible for concentrating urine34,35. Thus, inhibition of AQP1
is predicted to produce water diuresis by a mechanism that is different from conventional
salt transport-blocking diuretics, which suggests that AQP1 blockers could have clinical
potential in the refractory oedema that is associated with congestive heart failure and
cirrhosis.
AQP2, AQP3 and AQP4 are expressed in kidney collecting duct epithelial cells. Fluid
retention by the kidney (also known as antidiuresis) requires a high transepithelial
permeability to water in the collecting duct, which is accomplished by vasopressin-induced
trafficking of AQP2 from an intracellular vesicular compartment to the apical (that is,
lumen-facing) plasma membrane of the cell36; AQP3 and AQP4 are constitutively active as
water transporters on the basolateral (that is, blood-facing) cell membrane. Mice lacking
AQP2, AQP3 or AQP4 have defects in urine-concentrating function (albeit to varying
levels), and hence inhibition of these AQPs would produce an aquaretic response similar to
that produced by vasopressin V2 receptor antagonists37–40. Interestingly, when AQP11
(whose function is not fully understood) is deleted, mice develop renal and hepatic cysts
through as yet unknown mechanisms41.
AQPs facilitate the secretion of water into acini of glands following the creation of an
osmotic gradient by the active secretion of solutes (FIG. 3b). Mice lacking AQP5, which is
expressed in salivary and airway sub-mucosal glands, have defective secretion of saliva42
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and airway mucus43. Namely, the secretions are hyperosmolar and occur at lower levels
because the low water permeability of the gland acini in the absence of AQP5 prevents
osmotic equilibration across the epithelium. In addition, AQP1 facilitates the secretion of
aqueous fluid by the ocular ciliary epithelium44 and of cerebrospinal fluid by the choroid
plexus45. Therefore, AQP1 inhibition might reduce intraocular pressure in glaucoma and
intracranial pressure in brain trauma or stroke, whereas inhibition of AQP5 could reduce
salivation and airway mucus production during anaesthesia.
As suitable AQP inhibitors or neutralizing antibodies targeting AQPs are not available, and
informative gene knockdown studies have not been undertaken, the current knowledge about
the role of AQPs in epithelial fluid transport comes from studies carried out in knockout
mice.
CNS functions
AQP4 is the principal water channel expressed in astrocytes throughout the central nervous
system (CNS), particularly at astrocyte end-feet at the blood–brain barrier and the
ependymal–cerebrospinal fluid barrier4,46. There is evidence that AQP4 is involved in the
transport of water into and out of the brain and spinal cord, in neuroexcitation and in
astrocyte migration following injury (FIG. 3d,e). It has been proposed that AQP4
modulators have therapeutic potential in the treatment of brain oedema (of several
aetiologies), epilepsy and neural regeneration, as well as brain and spinal cord trauma47. As
AQP4 facilitates water movement across the blood–brain barrier, AQP4-deficient mice have
better survival and reduced accumulation of water in the brain than wild-type mice in
models of cytotoxic brain oedema (that is, models that involve cell swelling). These mouse
models of cytotoxic oedema include water intoxication, focal and global ischaemia and
bacterial meningitis48–51.
AQP4 also facilitates water exit from the brain in vasogenic oedema. In this process, water
moves into the brain by a bulk fluid flow mechanism through a leaky blood–brain barrier
and exits through the AQP4-rich glia limitans that lines the brain ventricles and the surface
of the brain52. AQP4-deficient mice have greater accumulation of water in models of
vasogenic brain oedema, including models of intraparenchymal fluid infusion, cortical-
freeze injury, brain tumour, brain abscess and subarachnoid haemorrhage52–55, as well as in
obstructive hydrocephalus56. AQP4 probably has a similar role in the spinal cord; deletion
of AQP4 reduces cytotoxic swelling and improves clinical outcomes in a mouse model of
spinal cord compression injury57, but increases vasogenic swelling in a mouse model of
spinal cord contusion injury58. To validate AQP4 as a drug target, it will be important to
investigate verified, selective AQP4 inhibitors when they become available.
AQP4-deficient mice also have altered neuroexcitation: namely, prolonged seizure
duration59 and cortical spreading depression60. AQP4 deficiency is associated with a slower
rate of potassium reuptake by astrocytes following neuroexcitation59,61, which — as
supported by mathematical modelling — may be related to a reduced electrochemical
driving force for potassium reuptake caused by slowed astrocyte water uptake and
contraction of the extracellular space62. AQP4-deficient mice also have impaired glial scar
formation, which may be related to defective astrocyte migration63,64. Reduced glial
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scarring caused by AQP4 inhibition may facilitate neural regeneration following brain or
spinal cord injury, or a stroke.
AQP1 is expressed in dorsal root ganglion neurons and nociceptive C-fibres65–67. An early
study reported that AQP1-null mice had reduced pain sensitivity65, but another study found
no effect of AQP1 deletion on pain perception67. It is now known that AQP1 deletion in
mice causes a selective reduction in thermal inflammatory pain and cold-induced pain,
which may involve an interaction between AQP1 and the voltage-gated sodium channel
Nav1.8 (also known as SCN10A)68. These findings raise the possibility of using AQP1
inhibitors as novel, non-narcotic analgesics.
Tumour angiogenesis and spread
AQPs are also involved in tumour angiogenesis, invasion, metastasis and growth. AQP1 is
highly expressed in tumour-associated microvascular endothelial cells69, and numerous
studies have shown that AQPs are highly expressed in several different tumour cell types. In
many tumours, the same AQPs are also expressed in the non-tumour cells from which the
tumour originates70. For example, AQP1 (REF. 71), AQP4 (REFS 72,73) and AQP9 (REF.
74), which are expressed in normal astrocytes, are often also expressed in human
astrocytomas, with AQP4 expression correlating with tumour severity72. Mice lacking
AQP1 have reduced growth of implanted and spontaneously generated tumours as a
consequence of defective tumour angiogenesis75,76. Also, implanted AQP1-expressing
tumours have greater local invasiveness and more metastases than tumours lacking AQPs77.
AQP-dependent cell migration, in which the polarization of AQPs to the leading edge of
migrating cells facilitates the entry of water into extending lamellipodia in the direction of
cell movement (FIG. 3c), is one mechanism that has been proposed to facilitate AQP1-
dependent tumour angiogenesis and metastasis78. Several studies show that AQP facilitates
the proliferation of some types of tumour cells through mechanisms that may involve altered
signalling pathways79–83. Remarkably, AQP3-deficient mice are resistant to the formation
of skin tumours following the administration of chemical stimuli; this resistance may result
from impaired glycerol uptake by tumour cells79.
These compelling observations suggest that AQP inhibitors have therapeutic potential in
oncology. Current treatments for glioblastoma either target rapidly dividing tumour cells
(such as radiotherapy, temozolomide or the combination of procarbazine, lomustine and
vincristine) or they inhibit angiogenesis (for example, bevacizumab). AQP inhibitors could
be unique in targeting infiltrating tumour cells, which might convert a tumour that diffusely
infiltrates into normal tissue — and that is not surgically excisable — into a tumour with a
distinct border. Whether AQP4 inhibitors could reduce the infiltration of glioblastoma cells
into normal brain tissue could be tested by the implantation of glioblastoma cells with
inducible AQP4 expression into the mouse brain. Switching off AQP4 expression, which is
equivalent to administering an AQP4 inhibitor, would be predicted to reduce tumour cell
infiltration into the normal brain tissue.
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Functions of AQP-facilitated glycerol transport
Mouse phenotype studies have clarified the functional significance of glycerol transport by
the aquaglyceroporins (FIG. 3f–h): namely, AQP3, AQP7 and AQP9.
AQP3 is expressed in the basal layer of proliferating epidermal keratinocytes. AQP3-
deficient mice have reduced hydration of the stratum corneum and reduced skin elasticity84.
Deficiency of AQP3 results in reduced permeability of epidermal cells to glycerol, which
consequently reduces the glycerol content of the stratum corneum and epidermis, in which
AQP3 normally acts as a water-retaining ‘humectant’. Normalization of the glycerol content
in the skin of AQP3-deficient mice by systemic replacement corrects skin dehydration and
related defects85. Several cosmetic companies have marketed anti-ageing formulations that
claim to contain natural-product enhancers of epidermal AQP3 expression86. However,
increasing AQP3 expression87 in the skin should be carried out with caution as AQP3 is
highly expressed in skin tumours, and AQP3 deficiency in mice greatly reduces the
formation of these tumours. Therefore, increasing AQP3 expression could increase the
formation of skin tumours. Moreover, AQP3 deficiency is associated with impaired
corneal88 and cutaneous89 wound healing in mice, and with impaired colonic epithelial cell
proliferation in a mouse model of colitis181. AQP3 is also expressed in immune cells, and its
deletion from these cells in mice impairs the function of macrophages91 and T cells29.
Because AQP3 has several roles, both beneficial and deleterious, establishing an acceptable
therapeutic window for an AQP3 modulator would be challenging.
The aquaglyceroporins AQP7 (expressed primarily in adipocytes) and AQP9 (expressed in
hepatocytes) are involved in adipose metabolism. AQP7-null mice have a progressive age-
related increase in adipose mass and adipocyte hypertrophy, with the accumulation of
glycerol and triglycerides in adipocytes92,93. AQP7 deficiency leads to reduced permeability
of the plasma membrane to glycerol, which causes cellular accumulation of glycerol and
triglyceride as well as upregulation of glycerol kinase expression. In humans, AQP7
expression in adipocytes is downregulated in obesity94. These results suggest that increasing
adipocyte AQP7 expression and/or function may be a novel approach for treating obesity95;
however, there is a lack of critical proof-of-concept data, such as the effects of AQP7
overexpression (induced by gene transfer) on adipocyte hypertrophy in obese mice. There is
evidence that AQP9 is involved in the hepatic uptake of glycerol and perhaps urea96,97, and
that AQP7 and AQP9 act as metabolic regulators in diabetes and obesity95. Nevertheless,
further work using clinically relevant animal models is needed to validate AQP9 as a drug
target.
AQP mutations in humans
Data from individuals with rare loss-of-function mutations in AQPs have provided important
information about the functions of AQPs in humans (TABLE 1). Humans and mice lacking
functional AQP0 have congenital cataracts90,98. The primary functions of AQP0 in the lens
may be in cell–cell adhesion of lens fibres and in the regulation of gap junction channels,
rather than in water transport99.
Verkman et al. Page 8
Nat Rev Drug Discov. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
A report of two individuals who lacked functional AQP1 showed that they had defective
urine-concentrating function100, as seen in AQP1-knockout mice32, but without other gross
abnormalities. As discussed further below, humans lacking functional AQP2 have the rare
genetic disorder NDI101. There are reports of individuals with an apparent lack of functional
AQP3 (REF. 102), but this study provided no information on their phenotype. Three
children with an AQP7 mutation were reported to manifest hyperglyceroluria and a defect in
ATP secretion by platelets103. Two recent studies showed that AQP5 mutations were
associated with the development of palmoplantar keratoderma, but it is unclear whether
these mutations affect the water permeability of AQP5 (REFS 104,105). Genetic studies
have sought to identify disease-relevant AQP polymorphisms in disorders including stroke,
migraine, Menière’s disease, NMO, temporal lobe epilepsy, cataracts, diabetes and obesity,
but compelling associations have not been found.
Aquaporin-targeted drugs: state of the art
Assays that measure the functions of AQPs are crucial for the screening and optimization of
small-molecule modulators. TABLE 2 summarizes the key features of assays that are used
for the primary screening of AQP modulators and assays of water transport function that are
used for the screening of AQP modulators.
Functional assays
Functional analysis of AQPs requires the measurement of membrane water (or glycerol)
permeability. One approach to determine water permeation is the measurement of water flux
across a tight (that is, non-leaky) cell layer, typically an epithelial cell cultured on a porous
support (FIG. 4a). In this approach, water flux is driven by a transepithelial osmotic gradient
using a membrane-impermeant solute such as sucrose or mannitol. The flux of water is
measured by the dilution of an indicator dye in the fluid volume on the small apical
surface106, or by measuring the height of the fluid in an Ussing chamber using electrical or
optical methods107. The measurement of transepithelial water transport is useful for
secondary assays but not for primary high-throughput screening because of the technical
complexity, the long-time needed for each measurement (tens of minutes), and the relatively
imprecise data generated.
Measuring the kinetics of the cell volume (or the membrane vesicle or reconstituted
proteoliposome volume) in response to a rapidly imposed osmotic gradient is a useful
approach for quantifying the permeability of cell membranes to water in primary screening
assays (FIG. 4b). Several approaches have been developed for following cell volume
kinetics, including image analysis, light scattering and interferometry in unlabelled
cells108,109 and reporter dye intensity in fluorescently labelled cells, as measured by total
internal reflection110.
Several approaches are suitable for primary functional screens of AQPs. In the calcein
method, AQP-expressing cells are grown as monolayer cultures on a solid support, such as a
multi-well plate, stained with calcein and then subjected to an osmotic gradient by the
addition of an anisosmolar (that is, hypo-osmolar or hyperosmolar) solution. Cytoplasmic
calcein fluorescence measures cell volume, as the fluorescence of calcein is quenched by
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cytoplasmic proteins whose concentrations change as cells shrink or swell111. A similar
method, which does not require dye loading, uses the genetically encoded, cytoplasmically
expressed yellow fluorescent protein YFP-H148Q–V163S, whose fluorescence is quenched
by chloride112. The fluorescence of YFP-H148Q–V163S provides a read-out of cell volume
because the cytoplasmic chloride concentration changes as cells shrink or swell113,114. Both
the calcein- and YFP-based approaches rely on kinetic measurements of fluorescence
following the addition of anisosmolar solution; hence, the osmotic response of the cell must
be sufficiently slow (approximately a few seconds) for accurate analysis, and the time taken
to mix the solution must be short compared to the osmotic equilibration time.
A simple method that relies on a single read-out of cell volume, rather than a kinetic
analysis, involves measuring cell lysis in response to an osmotic gradient of a permeant
solute (FIG. 4c). In this method, erythrocytes, which natively express AQP1 and urea
transporter B (UTB; also known as SLC14A1), are preloaded with the urea analogue
acetamide, which is transported by UTB and equilibrates across the erythrocyte membrane
over a time period slightly slower than that of water. Dilution of erythrocytes into an
acetamide-free solution results in rapid, AQP1-dependent cell swelling and lysis. Reduced
water permeability of AQP1 (for example, caused by AQP1 blockers) prevents cell lysis, as
water influx is slower than the dissipation of the osmotic gradient by acetamide efflux. The
extent of cell lysis is quantified by a single read-out of near-infrared light absorbance. The
erythrocyte lysis assay has been used to identify UTB inhibitors that had nanomolar potency
and increased cell lysis115. From a screening of 100,000 small molecules for AQP1
inhibitors, preliminary results produced a few weakly active compounds (A.S.V.,
unpublished observations).
Each of the above methods has potential limitations (TABLE 2). Not discussed here are
possible methods using glycerol transport assays that could be used for functional screens of
aquaglyceroporin modulators. Measurements of transepithelial water permeation are useful
for the verification of compounds that were active in primary screens (as discussed above),
although stopped-flow measurements of cell volume kinetics (measured by a light scattering
read-out) in response to rapidly imposed osmotic gradients are, in our view, better. Stopped-
flow measurements can be made in plasma membrane vesicles from AQP-expressing
cells116, in reconstituted proteoliposomes117 or in small cells such as erythrocytes115.
Swelling kinetics in Xenopus laevis oocytes that express AQPs (induced by the injection of
complementary RNA) has been used in several studies of AQP modulators. Swelling
kinetics is deduced by image analysis of a cross-sectional area of an oocyte using low
magnification and low numerical aperture objectives118,119. Although oocyte swelling is
useful for detecting large differences in water permeation, as used in the original
identification of AQP1 as a water channel120, it is of limited value for the study of AQP
modulators as it produces artefacts. As discussed116, apparent oocyte swelling depends not
only on water permeability but also on other factors such as solute transport, oocyte
geometry, the physical properties of the plasma membrane as well as cytoplasmic and
extracellular unstirred layers (that is, aqueous layers in which solute transport is diffusion-
limited), each of which can be influenced by a putative AQP modulator. In addition, the
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strict technical details about how oocyte swelling measurements should be performed (as
discussed below) have not been adhered to in most published reports.
AQP inhibitors
As discussed below, the identification of AQP modulators has turned out to be unexpectedly
challenging. Four classes of AQP-targeted small molecules have been described: cysteine-
reactive heavy metal-based inhibitors; small-molecule scaffolds that are reported to inhibit
water conductance; small molecules that target the interaction between AQP4 and the NMO
autoantibody; and agents that act as chemical chaperones to facilitate the cellular processing
of NDI-causing AQP2 mutants (FIG. 5).
The inhibition of water permeation into erythrocytes (which express AQP1) by sulphydryl-
reactive heavy metal ions and organomercury compounds, such as pCMBS (p-
chloromercuribenzene sulphonate), has been appreciated for over 40 years121. The inhibition
of AQP1 by mercury(II) chloride involves a covalent interaction with Cys189, which is
thought to sterically occlude the water pore122,123. A mutation in the Cys189 residue of
AQP1 prevent its inhibition by mercury, and other AQPs (such as AQP4) that lack a
cysteine residue at this position are resistant to inhibition by mercury124. Other heavy metals
such as silver (in silver nitrate and silver-sulphadiazine)125 and gold(III) (in the compounds
Au(phen), Au(bipy), Au(bipy)Me, Au(bipy)NH2 and Au(terpy))126 also inhibit some AQPs
(FIG. 5). It was suggested that these inhibitors might interact with a cysteine residue near the
conserved NPA domain125.
Gold-containing compounds were reported to inhibit AQP3, with Au(phen) being the most
potent in the series126,127. Interestingly, Au(phen) inhibits glycerol permeation through
AQP3 to a greater extent than water permeation, which suggests that steric occlusion of the
channel by Au(phen) is insufficient to block water transport. Computational modelling
suggested that gold-based inhibitors interact with Cys40, which is present in the
extracellular domain of AQP3 (REF. 127). Although heavy metal-containing drugs are
generally toxic, there are drugs with clinically acceptable toxicity, such the chemotherapy
drug cisplatin. In addition, other organometallic compounds that contain gold128,129 and
ruthenium130 have been described as potential anti-cancer agents with minimal toxicity. It is
notable that mercury(II) chloride was used historically to treat syphilis before the discovery
of penicillin, and as a diuretic before the discovery of thiazides and loop diuretics.
Several studies have described small-molecule inhibitors of water permeability in AQP-
expressing X. laevis oocytes, which do not contain metals. One such class is the non-
selective tetraalkylammonium ion channel blockers such as tetraethylammonium (TEA+).
TEA+ was reported to be a reversible inhibitor of AQP1 (REF. 131), and later found to be a
blocker of AQP1, AQP2 and AQP4 (REF. 132). A tentative TEA+ binding site was
proposed based on the resistance of a mutant AQP1 (with a mutation at the Tyr186 site) to
TEA+ (REFS 131,132). The carbonic anhydrase inhibitor acetazolamide has been reported
to inhibit AQP1 expressed in X. laevis oocytes133 and in AQP1-transfected human
embryonic kidney 293 (HEK293) cells134. Acetazolamide and a related sulphonamide135, as
well as several anti-epileptic drugs136, were reported to inhibit AQP4 expressed in X. laevis
oocytes. The loop diuretic bumetanide was reported to be a weak inhibitor of AQP4
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expressed in X. laevis oocytes (with an IC50 value of >100 μM), and a synthesized analogue
(AqB013) had an IC50 value of ~20 μM for AQP1 and AQP4 (REF. 137). The same group
found that another analogue (AqF026) slightly increased AQP1-mediated oocyte
swelling138. The loop diuretic furosemide was also shown to weakly inhibit AQP1
expressed in X. laevis oocytes139. In our view, it is unexpected that many common drugs
that target various structurally and functionally unrelated membrane proteins were reported
to inhibit or increase AQP-mediated water transport.
Unfortunately, follow-on studies of these putative AQP modulators — using alternative
functional assays that are less prone to artefacts — have failed to verify AQP inhibition. For
example, in an assay using purified human AQP4 reconstituted into liposomes, TEA+ was
inactive at concentrations of up to 10 mM10. There was no inhibition of AQP1 by
acetazolamide (at concentrations of up to 1mM) when measured by pressure-induced
haemolysis of erythrocytes140. In addition, acetazolamide and TEA+ were inactive when
tested at concentrations of up to 10 mM by stopped-flow light scattering in erythrocytes,
which natively express AQP1, and in epithelial cells that were stably transfected with AQP1
(REF. 141). Another report re-examined the activity of putative AQP1 inhibitors in X. laevis
oocytes (the cells that were originally used to show the activity of the inhibitors) using a
high-resolution method to measure osmotic water permeation142. This study found that
acetazolamide and TEA+ (at concentrations of up to 100 μM and 500 μM, respectively) did
not inhibit AQP1(REF. 142). Although the authors considered several explanations for this
result, they posited that earlier studies that used lower-sensitivity techniques could have
been susceptible to secondary effects related to the distribution of ions across the plasma
membrane142.
Preliminary work re-examining the effects of various loop diuretics and their analogues in
several systems showed no AQP-mediated inhibition or augmentation of water transport
(A.S.V., unpublished observations). The series of aryl sulphonamides and anti-epileptics that
were reported to inhibit AQP4 in X. laevis oocytes135 were inactive at concentrations of up
to 100 μM when they were re-evaluated using plasma membrane vesicles from AQP4-
transfected mammalian cells and primary cultures of human glial cells143. Finally, a study
using AQP4-expressing X. laevis oocytes found that AQP4–IgG (immunoglobulin G)
autoantibodies in NMO inhibited AQP4-mediated water transport140, although this finding
was not repeated in studies that used assays that are less prone to artefact116,141.
Recently, several AQP1 inhibitors were identified142 in a virtual screen of 1,000,000
compounds from the University of California, San Francisco (UCSF)’s ZINC database143;
the screen was carried out to identify compounds that bound to the extracellular vestibule of
AQP1. Out of 14 hit compounds that were tested further, three structurally unrelated
compounds were reported to inhibit the osmotic swelling of AQP1-expressing X. laevis
oocytes; these compounds included m-benzene diacrylic acid (BZDA), which had an IC50
value of ~8–18 μM. However, none of these compounds inhibited AQP1-mediated water
permeation when it was tested in a definitive erythrocyte stopped-flow assay142. This result
mirrors the concerns mentioned above about potential artefacts that can occur when the
oocyte swelling assay is used.
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A medium-throughput assay that used calcein fluorescence in cells expressing AQP1 or
AQP4 (REF. 144) screened 3,575 small molecules, including 418 US Food and Drug
Administration (FDA)-approved drugs, for inhibition of water transport. This yielded four
distinct scaffolds, including NSC168597, NSC670229 and NSC164914, which had IC50
values of ~ 27–49 μM in water transport assays in rat erythrocytes. In another recent study
that used homology modelling, molecular dynamics, computational docking and site-
directed mutagenesis to identify AQP9 inhibitors145, an initial screen of ~1,000,000
compounds identified six AQP9 candidate inhibitors. These included the representative
compound ID4, which had an IC50 value of ~ 4–10 μM in calcein fluorescence assays in
AQP9-expressing Chinese hamster ovary (CHO) cells. Independent verification of AQP
inhibition by these compounds is awaited.
AQPs are challenging drug targets
Progress in the identification of agents that modulate water permeation through AQPs has
been remarkably slow compared to modulators of other channel proteins. This is partly due
to the challenges of water permeation assays, which are fraught with potential artefacts;
furthermore, unlike for electrophysiological assays of ion transport, robust gold-standard
assays of AQP activity are not available. We think that the over-reliance on X. laevis oocyte
and calcein-based assays has produced candidate AQP inhibitors that have not been verified
by subsequent measurements because there are multiple, water-transport-independent
determinants of oocyte swelling rates and calcein fluorescence signal.
The hit rate for the identification of small-molecule AQP inhibitors appears to be very low
compared to that for other membrane proteins such as ion channels, solute transporters and
membrane receptors. Perhaps the small size of the functional AQP monomer and its very
small pore diameter, which prevents the access of small molecules, translates to poor
druggability. As AQPs are simple passive pores, they lack sophisticated gating and transport
mechanisms that can be targeted by small molecules. Furthermore, because AQPs transport
small, neutral molecules, electrostatic interactions are limited to those between hydrogen-
bond donors and acceptors, rather than interactions involving charges. Last, mutations in the
extracellular and cytoplasmic domains of AQPs generally have little effect on water
permeability through the channel, which suggests that the binding of an inhibitor should
occur deep in the narrow AQP pore to physically prevent water conduction.
Further large-scale screening of random and computationally biased libraries is needed, as
well as rigorous validation of compounds that have apparent activity using definitive assays
of AQP-mediated water (or glycerol) transport. In addition, as several human AQP
homologues exist, many with a wide tissue distribution, functional testing of verified
inhibitors against one AQP isoform should be carried out against a panel of the major AQPs.
AQP gene transfer
AQP gene transfer has been considered for treating salivary gland hypofunction, which is a
common side effect of radiation therapy for head and neck cancer. Radiation damages the
acinar cells that secrete saliva, largely sparing salivary duct cells, so drugs that stimulate
saliva secretion by targeting acinar cells are generally ineffective. In irradiated salivary
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glands, the osmotic pressure of the duct lumen is greater than that of the interstitium, which
has provided the rationale for increasing water movement across the duct cells into the
lumen by AQP1 gene transfer. This idea is supported by the observation that adenovirus-
mediated transfer of human AQP1 cDNA into the parotid glands of rats146 and miniature
pigs147 by retrograde infusion into the parotid duct partially restored saliva secretion after
radiation therapy for head and neck cancer. A Phase I clinical trial of adenovirus-mediated
AQP1 cDNA transfer to previously irradiated parotid glands in eleven participants148
showed that there was an objective increase in saliva flow in six individuals and a subjective
improvement in five individuals. However, there are major challenges associated with AQP
gene transfer, including targeting the correct cell type, achieving efficient transfection,
producing a sustained therapeutic effect and avoiding immune activation. In the Phase I
clinical trial, parotiditis was observed in eight of the eleven participants.
Aquaporinopathies as targets for AQP modulators
Here, we discuss two aquaporinopathies — NMO and NDI — in which progress has been
made in developing AQP-based therapeutics.
NMO: an autoimmune disease caused by AQP4-specific antibodies
NMO is an autoimmune inflammatory disease of the CNS that leads to paralysis and loss of
vision. Most cases of NMO are associated with the presence of an IgG1 antibody, termed
AQP4–IgG (or NMO–IgG)149, which binds to conformational epitopes on the extracellular
surface of AQP4 (REFS 150–153) and, when injected in mice, produces the histological
features of human NMO lesions154. The working hypothesis for NMO pathogenesis
involves the entry of AQP4–IgG into the CNS and its binding to AQP4 on perivascular
astrocyte end-feet, which leads to activation of the classical complement cascade, an
inflammatory response that is accompanied by marked granulocyte and macrophage
infiltration, as well as secondary oligodendrocyte damage, demyelination and neuron
death152. Current NMO treatments include immunosuppression (that is, administration of
corticosteroids, azathioprine, methotrexate, cyclophosphamide, mycophenolate or
mitoxantrone), depletion of CD20+ B cells (using rituximab) and plasma exchange155.
Based on progress in understanding the mechanisms that underlie NMO pathogenesis, new
NMO therapeutics are being investigated that target AQP4, AQP4–IgG and various
mediators of cytotoxicity and inflammation (FIG. 6a). One AQP4-targeted strategy involves
using monoclonal antibodies to block the binding of AQP4–IgG to AQP4, which is the
initiating event in NMO pathogenesis. A recombinant monoclonal antibody against AQP4–
IgG has been engineered, called aquaporumab, which binds tightly to AQP4 but lacks
cytotoxic effector functions156. Because of the small extracellular footprint of AQP4,
aquaporumab competes sterically with pathogenic, polyclonal AQP4–IgG. Aquaporumab
prevented the formation of NMO lesions in ex vivo spinal cord slices and in mice in vivo156.
As an alternative approach, a small-molecule screen identified compounds that bind to
AQP4 and inhibit AQP4–IgG binding without affecting the surface expression or water
permeability of AQP4. However, the compounds that were identified in the initial screen,
including the antiviral arbidol, the flavonoid tamarixetin and several plant-derived
berbamine alkaloids, have relatively low potency and CNS penetration157.
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Another approach for reducing AQP4–IgG binding involves neutralizing the pathogenic
AQP4–IgG with bacteria-derived endoglycosidase158 or with the Streptococcus pyogenes
IgG-degrading enzyme IdeS159. Endoglycosidases cause selective deglycosylation of the
IgG heavy chain, which eliminates the complement-dependent cytotoxicity and antibody-
dependent cell-mediated cytotoxicity effector functions of the antibody. IdeS cleaves IgG
antibodies into Fc and F(ab′)2 fragments. The resulting non-pathogenic AQP4–IgG (that is,
deglycosylated AQP4–IgG or AQP4–IgG–F(ab′)2) binds to AQP4 in cultured cells with an
affinity that is comparable to that of the intact pathogenic AQP4–IgG, thus competing with
pathogenic AQP4–IgG for AQP4 binding. These AQP–IgG-targeted enzymatic therapeutics
might be applied by therapeutic apheresis. As NMO is a rare disease, funding the
development of novel treatments is difficult, as is carrying out clinical trials.
Other potential therapeutic strategies for NMO include reducing the expression of AQP4 on
astrocytes or preventing its supramolecular assembly in orthogonal arrays160, upregulating
complement inhibitor proteins such as CD59 or reducing the entry of AQP4–IgG into the
CNS (FIG. 6a). Tocilizumab, a humanized monoclonal antibody that targets the
interleukin-6 receptor (IL-6R), reduces the survival of AQP4–IgG-secreting plasmablasts in
vitro161, and case reports show that patients treated with this antibody have reduced NMO
symptoms162,163. As AQP4-targeted therapies are more selective than general
immunosuppressive agents or complement- or leukocyte-targeted therapies, they may have
fewer side effects.
NDI: a genetic disorder caused by loss-of-function AQP2 mutations
Loss-of-function mutations in AQP2 cause NDI, an autosomal hereditary disease that is
characterized by severe polyuria and polydipsia, which — if inadequately treated — lead to
recurrent dehydration in early life and cognitive deficits. NDI that is caused by an AQP2
mutation is very rare, with an incidence of ~1 in 20 million births164,165. Normally,
regulation of water permeation in the renal collecting duct epithelium is mediated by the
binding of vasopressin to V2 receptors at the basolateral membrane, which causes exocytic
insertion of intracellular AQP2-containing vesicles into the apical plasma membrane of the
cell, primarily through cyclic AMP signalling36 (FIG. 6b). Water then moves from the
tubule lumen into the bloodstream across constitutively active AQP3 and AQP4 on the
basolateral membrane, and through AQP2 on the apical membrane, producing concentrated
urine. Hereditary NDI is also caused by a mutation in the gene encoding the V2 receptor
(AVPR2), with an incidence of ~1 in 2 million births. Fluid replacement is the mainstay of
therapy for NDI caused by mutations in AQP2 or AVPR2; thiazide diuretics are used to
impair the maximal ability to dilute urine and reduce urine output164. Novel therapeutic
approaches that are under consideration for NDI caused by loss-of-function AVPR2
mutations include pharmacological chaperones (that is, V2 receptor antagonists)166 and the
targeting of alternative G protein-coupled receptors in the collecting duct to restore cAMP
signalling167.
The treatment of NDI caused by AQP2 mutations presents a greater challenge. Mutations in
AQP2 have been described that lead to an autosomal recessive trait involving defective
cellular processing or functioning of AQP2, or an autosomal dominant trait in which mutant
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AQP2 prevents the targeting of wild-type AQP2 on the plasma membrane165. The
AQP2T126M mutation causes misfolding of AQP2 and leads to its retention at the
endoplasmic reticulum168, similarly to the ΔF508 mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene that causes cystic fibrosis. Incubation of
AQP2T126M-expressing cells with non-selective chemical chaperones, including glycerol
and trimethylamine oxide (TMAO) (FIG. 5d), rescued the cellular processing defect,
allowing the insertion of AQP2T126M into the plasma membrane and the restoration of
cellular water permeability. A small screen of approved and investigational drugs identified
the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxy-geldanamycin
(17-AAG) as a corrector of AQP2T126M processing, which partially corrected NDI in
transgenic mice with the AQP2T126M mutation40. As NDI caused by an AQP2 mutation is
very rare, repurposing of existing drugs is a more practical approach than the development
of a new chemical entity.
Non-mammalian aquaporins as drug targets
AQPs are found in disease-causing bacteria (AqpZ and GlpF in Escherichia coli)169,170,
protozoan parasites that cause malaria (PfAQP in P. falciparum)171 and toxoplasmosis
(TgAQP1 in Toxoplasma gondii)172, as well as in parasitic worms that cause Chagas disease
(TcAQP1, TcAQP2 and TcAQP3 in Trypanosoma Cruzi)173, sleeping sickness (TbAQP1,
TbAQP2 and TbAQP3 in Trypanosoma brucei)174 and schistosomiasis (SmAQP in
Schistosoma mansoni)175. In addition to facilitating water transport, many parasitic AQPs
are permeable to glycerol and lactate. In general, AQP deletion in parasites is not lethal, but
it reduces parasite growth and virulence, and hence these attenuated parasitic forms could be
used in vaccines. However, parasitic AQPs seem to be the major entry routes of cytotoxic
drugs into the parasite172–176, and AQP deletion renders the parasites relatively resistant to
treatments with hydroxyurea, dihydroxyacetone and the trivalent metalloids arsenic and
antimony.
Host AQPs are potential drug targets for the treatment of parasitic infections. For example,
the human malarial parasite that resides within erythrocytes relies on AQP3 and AQP9 in
the erythrocyte plasma membrane to obtain glycerol. The possibility of using AQP3 and
AQP9 inhibitors as antimalarial agents has been proposed177, but further work is needed to
understand the role of host versus parasite AQPs in the metabolic processes within the
parasite.
Further directions and challenges
The in vitro data and results from studies in animal models indicate compelling
opportunities for AQP-targeted therapeutics. Perhaps the best validated indications for AQP
inhibitors include refractory oedema, tumour angiogenesis and spread, neuroprotection and
glaucoma. Enhancement of AQP function, by upregulating AQP expression or possibly by
gene transfer, may be beneficial in obesity, tumour-associated vasogenic brain swelling,
salivary and/or lacrimal gland dysfunction and wound healing. An as yet unexplored
possibility is the application of an AQP-targeted antibody conjugated to a toxin for tumour
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therapy, such as aquaporumab–toxin conjugates for the treatment of AQP4-expressing
glioblastomas. Additional potential indications of AQP modulators are listed in TABLE 1.
However, progress in this field has been slow. As discussed above, challenges in developing
small-molecule AQP inhibitors include conceptual and technical issues associated with
screening assays, as well as the apparent poor druggability of AQPs. The existence of 13
homologous human AQP isoforms, many of which have broad tissue distributions, presents
a further challenge in minimizing the off-target effects of AQP modulators. The topical
application of AQP modulators for the treatment of glaucoma or cutaneous diseases may
reduce this challenge, as might targeting renal tubules that are in contact with drug-enriched
luminal fluid. Notwithstanding these challenges, the risk–reward ratio seems to be
favourable for further exploration of AQPs as drug targets, which may include large-scale
functional screens of diverse compound collections as well as computationally biased
screening driven by high-resolution AQP crystal structure data.
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Glossary
Aquaglyceroporin A class of the aquaporins (AQP3, AQP7 and AQP9) that
transport glycerol in addition to water
Virtual screening A computational technique that is used to identify small-
molecule modulators of a drug target. This is typically
conducted in a structure-based manner (using protein–ligand
docking) or in a ligand-based manner (using similarity
searching or through the use of pharmacophore models)
Molecular dynamics
simulations
Computational methods that simulate the physical motion of
atoms and molecules. When applied to biomolecules, the
results are typically trajectories of the atoms of the protein,
solvent, ions, bound ligands and so on, over timescales that
range from nanoseconds to microseconds
Grotthuss-type
‘proton-wire’
mechanism
A hypothesis for proton movement in bulk water, where a
proton can ‘hop’ along a continuous line of water molecules in
a hydrogen-bonded network, with the resultant reorientation of
water molecules after the transfer has occurred
Free-energy profiles A term that is used to describe the estimated energetics of a
molecule passing through the span of a channel protein; it is
usually calculated by molecular dynamics simulations
Salt transport-blocking
diuretics
Drugs that inhibit the absorption of Na+, K+ and Cl− ions in the
kidney and therefore secondarily inhibit water absorption. For
example, amiloride inhibits the epithelial sodium channel in
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the distal tubule, and furosemide inhibits the Na+/K+/2Cl−
symporter in the thick ascending limb of the loop of Henle
Aquaretic response The urinary elimination of water without electrolyte loss (as
opposed to a diuretic response in which urinary elimination of
water is secondary to the elimination of salt)
Astrocyte end-feet Astrocyte processes that surround microvascular endothelial
cells in the central nervous system
Vasogenic oedema Oedema in the central nervous system where water
accumulates in extracellular spaces
Cortical spreading
depression
A wave of depolarization that spreads in the brain and is
followed by the suppression of brain activity
Glial scar A scar in the central nervous system that is formed in response
to damage and involves reactive astrocytes and microglia
Density functional
theory calculations
A computational method that uses quantum-mechanical theory
to model the energy and chemical structure of molecules
Infiltrating tumour
cells
Tumour cells that spread into normal tissue such that there is
no clear border between the tumour and the normal tissue
Stratum corneum The outermost layer of the epidermis that is composed of dead
cells (that is, keratinocytes)
Lens fibres Long, thin transparent cells that form the bulk of the lens,
arranged in concentric layers
Gap junction channels Intercellular channels composed of connexin proteins that
allow the passage of small molecules (typically <1 kDa)
between cells
Palmoplantar
keratoderma
A disease that is characterized by abnormal thickening of the
skin on the palms of hands and soles of feet
Ussing chamber An apparatus in which a cell layer separates two solution
compartments; it is used to measure ion transport
Stopped-flow
measurements
Assays that are carried out using an apparatus in which two
solutions are mixed together rapidly (in <1 millisecond) and
have an optical read-out
IC50 value The concentration of a compound that produces 50% inhibition
of a target function
Parotiditis Inflammation of the parotid salivary gland
Therapeutic apheresis The passage of blood through a filtering apparatus to remove
or inactivate a pathogenic substance
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Figure 1. Structure of aquaporins
a | A top view of the extracellular face of an aquaporin 1 (AQP1) homotetramer, with
monomers labelled 1–4, based on the X-ray structure of bovine AQP1 (Protein Data Bank
(PDB) code: 1J4N). The tetrameric structure was modelled by the interactive PDBePISA
(proteins, interfaces, structures and assemblies) tool. b | A schematic of AQP membrane
topography. c | Structure of the bovine AQP1 monomeric unit, which shows key helical
domains (labelled M1–M8) and connecting linkers (labelled a–e). d | A view into the
extracellular vestibule of bovine AQP1. The constriction region (in green) is made up of
aromatic and arginine residues (known as the ar/R constriction; residues Phe58, His182 and
Arg197); extracellular Asn-Pro-Ala (NPA) residues (Asn194, Pro195 and Ala196) are
shown in orange; backbone α-carbonyl hydrogen-bond acceptors (Ile192, Cys191, Gly190
and Gly189) are shown in violet; and hydrophobic side chains comprising nonpolar
amphipathic surface are shown in black.
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Figure 2. Tissue distribution of mammalian aquaporins
In the central nervous system (CNS), aquaporin 1 (AQP1) is expressed in the choroid
plexus, and AQP4 is expressed on astrocyte end-feet and glia limitans. In the eye, AQP0 is
expressed in the lens, AQP1 is expressed in the corneal endothelium, AQP3 is expressed in
the conjunctiva and corneal epithelium, AQP4 is expressed in the retinal Muller cells and
lacrimal gland, and AQP5 is expressed in the corneal epithelium and lacrimal gland. In
salivary glands, AQP4 is found in the duct cells and AQP5 is expressed in the acini. In the
inner ear, AQP4 is expressed in the Claudius, Hensen and inner sulcus cells. AQP4 is
expressed in olfactory epithelial cells. AQP1 is expressed in the pain-processing C-fibres of
the spinal cord dorsal horn. AQP1 is expressed in all vascular endothelial cells except in the
CNS. AQP4 is expressed in the parietal acid-secreting cells of the stomach. In the lung,
AQP3 is expressed in the submucosal glands, AQP4 is expressed in the airway cells, and
AQP5 is expressed in the alveolar type I cells. Erythrocytes express AQP1, AQP3 and
AQP9. In the kidney, AQP1 is expressed in the proximal tubule, thin descending limb of the
loop of Henle and vasa recta, AQP2 is expressed in the luminal side of collecting duct
principal cells, AQP3 and AQP4 are found in the basolateral side of collecting duct principal
cells, and AQP7 is expressed in the S3 segment of the proximal tubule. AQP3 is expressed
in macrophages and T cells. In the skin, AQP3 is expressed in epidermal cells, primarily in
the stratum basale. Adipocytes express AQP7. Tumour cells express several types of AQPs;
for example, glioblastoma cells express AQP1, AQP4 and AQP9, whereas AQP1 is
Verkman et al. Page 30
Nat Rev Drug Discov. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
expressed in the microvascular endothelium of tumours in general. AQP4 is expressed on
the fast twitch fibres of skeletal muscle. AQP3, AQP4 and AQP8 are expressed in the
epithelial cells of the intestine. CSF, cerebrospinal fluid; DRG, dorsal root ganglion.
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Figure 3. Major physiological functions of aquaporins
a | In kidney tubules and microvessels, a high transepithelial water permeability in the
proximal tubule, thin descending limb of the loop of Henle, vasa recta and collecting duct is
required for urine-concentrating function. b | During fluid secretion by epithelial cells, a
high transepithelial water permeability facilitates the active secretion of near-isosmolar
fluid. c | Aquaporin (AQP)-facilitated cell migration involves the entry of water into
protruding lamellipodia in migrating cells. d | Water permeation across the blood–brain
barrier and the blood–CSF (cerebrospinal fluid) barrier (that is, the ependyma and sagittal
sinus) facilitates the movement of water into and out of the brain. e | AQP4-facilitated water
transport in astrocytes during potassium reuptake following neuroexcitation causes
contraction of the extracellular space, maintaining the driving force for potassium reuptake.
f | AQP3 facilitates skin hydration by maintaining high glycerol levels in the stratum
corneum, which acts as a humectant to retain water. g | AQP3 maintains high cellular
glycerol levels for the generation of ATP and lipid biosynthesis, which leads to cellular
proliferation. h | AQP7 facilitates the exit of glycerol from adipocytes, preventing the
intracellular accumulation of glycerol and triglyceride. FFA, free fatty acid.
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Figure 4. Assays of aquaporin-mediated water transport
a | An assay of water transport across a tight epithelial cell monolayer in response to a
transepithelial osmotic gradient. b | Methods based on changes in cell volume in response to
an osmotic gradient. Water efflux in response to an osmotic gradient, which causes cell
shrinkage, can be measured in suspended cells, vesicles or liposomes (top panel) or an
adherent cell layer (bottom panel). c | An assay that produces a single-point read-out of
aquaporin 1 (AQP1)-mediated water transport in erythrocytes, which natively express AQP1
and urea transporter B (UTB). The dilution of acetamide-loaded erythrocytes into an
acetamide-free solution causes a rapid water influx, cell swelling and lysis; AQP1 inhibition
prevents lysis. Osm, osmolality; TIRFM, total internal reflection fluorescence microscopy;
YFP, yellow fluorescent protein.
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Figure 5. Putative aquaporin-targeted small-molecule modulators
a | Cysteine-reactive, heavy-metal-based aquaporin (AQP) inhibitors121,123,125–127. b |
Proposed small-molecule AQP inhibitors and activators 131,132,134,137,139,142–145. c | Small
molecules that inhibit the binding of an AQP4 IgG (immunoglobulin G) autoantibody to
AQP4 in neuromyelitis optica157. d | Chemical chaperones that facilitate trafficking of
misfolded AQP2 mutants to the plasma membrane in nephrogenic diabetes insipidus40,168.
BZDA, m-benzene diacrylic acid; pCMBS, p-chloromercuribenzene sulphonate; TEA+,
tetraethylammonium; TMAO, trimethylamine N-oxide.
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Figure 6. AQP4-targeted therapies for neuromyelitis optica and nephrogenic diabetes insipidus
a | An illustration of the mechanism that underlies neuromyelitis optica (NMO)
pathogenesis, in which aquaporin 4 (AQP4)–IgG (immunoglobulin G) production and
subsequent binding to AQP4 is followed by the activation of complement and leukocyte
infiltration. NMO therapeutics are shown in boxes. These include drugs and therapies that
target AQP4 production (namely, rituximab, tocilizumab and plasma exchange; currently
used treatments), the binding of AQP4–IgG to AQP4 (aquaporumab, endoglyosidase S
(EndoS) and the Streptococcus pyogenes IgG-degrading enzyme IdeS; potential treatments),
complement activation (eculizumab, a complement C1-targeted monoclonal antibody (mAb)
and the C1 esterase inhibitor; potential treatments), molecules that disrupt the formation of
orthogonal arrays of particles (OAPs; a potential treatment), complement inhibitors (CD46,
CD55 and CD59; potential treatments) and inhibitors of leukocyte activity (sivelestat and
cetirizine; potential treatments). General immunosuppressive agents are shown as well. The
Fcγ receptor on immune cells binds to the constant part of IgG. The Fcγ receptor on immune
cells (neutrophils, eosinophils and macrophages) binds to the constant part of AQP4–IgG. b
| A schematic showing the cellular processing of AQP2 in epithelial cells of the renal
collecting duct. In response to vasopressin, which causes intracellular cyclic AMP elevation
and protein kinase A (PKA)-induced phosphorylation, AQP2-containing vesicles are
targeted to the plasma membrane and inserted into the apical plasma membrane of the cell.
Nephrogenic diabetes insipidus (NDI) can be caused by AQP2 mutations; some mutations
cause AQP2 misfolding and endoplasmic reticulum-dependent degradation. The action of
chemical or molecular chaperones on the mutant AQP2 can correct mutant AQP2
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misfolding. AC, adenylyl cyclase; C5b9, complement C5b9 membrane attack complex;
IL-6, interleukin-6; V2 receptor, vasopressin V2 receptor.
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Table 2
Assays of AQP water transport function
Cellular system Assay Throughput Advantages Limitations
Suspensions of
proteoliposomes,
vesicles or small cells
Stopped-flow (measured
by light scattering or
fluorescence quenching)
Low Quantitative, low variability in data,
good for all transport rates
Technically challenging,
requires specialized
instrumentation
AQP-expressing
Xenopus laevis
oocytes
Cell swelling following
osmotic challenge
(measured by image
analysis)
Low Applicable to any AQP that can be
expressed in oocytes
Technically challenging, high
variability of data, fraught
with artefact because there
are many determinants of
oocyte swelling
Cell monolayers
grown on a porous
filter
Transepithelial water
flow in response to
osmotic gradient
(measured by indicator
dilution)
Low Not subject to artefact Labour intensive, requires
cell lines with AQP
expression on all plasma
membranes, highly variable
data
Cell monolayers
grown on a solid
support
Volume kinetics
following osmotic
challenge (measured by
cytoplasmic calcein or
YFP fluorescence)
High Technically simple Requires stable expression of
AQP at an appropriate level,
potential artefacts due to the
effects of the compound on
indicator fluorescence
Cell monolayers
grown on a solid
support
Volume kinetics
following an osmotic
challenge (measured by
cytoplasmic fluorescent
dye)
High Reliable, relatively artefact-free Requires stable AQP
expression at appropriate
level, requires total internal
reflection fluorescence optics
Erythrocytes Lysis of acetamide-
loaded erythrocytes
following an osmotic
challenge
High Technically simple, single-point read-
out, relatively artefact-free
Only applicable for AQP1,
semi-quantitative read-out of
cellular lysis
AQP, aquaporin; YFP, yellow fluorescent protein.
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